To further validate the role of phospho-MARCKS in conveying paclitaxel resistance in breast cancer cells, we performed a dose-course analysis of MDA-MB-468 cells undergoing paclitaxel treatment. The gene discussed is MARCKS; the disease is breast carcinoma.